Shivam Saklani

Alivus Lifesciences (formerly knows as Glenmark Lifescience Ltd) is primarily engaged in Active Pharmaceutical Ingredient (API) manufacturing, serving both generic and innovator pharmaceutical companies. The company has a portfolio of high value, non-commoditized APIs in chronic therapeutic areas, namely Cardiovascular (CVS) disease, Central Nervous System (CNS) disorders, Pain Management, Oncology, Diabetes and Urology. History The company’s journey began over 22 years ago when Glenmark Pharmaceuticals (GPL) established its API (Active Pharmaceutical Ingredients) business. Initially, Glenmark acquired the Kurkumbh site to support its API needs. Over time, the API division expanded its R&D and operations to serve both Glenmark and external customers. In 2019, Glenmark Life Sciences became an independent company, separating from Glenmark Pharmaceuticals. This transition allowed GLS to focus solely on APIs, making it a trusted global supplier. The company began building a stro...

The share market, where everyone believes a person can earn a lot of money, is not in a good condition. The market has disappointed investors and speculators since the beginning of this year. Nifty 50 has fallen by 3.49% since the beginning of the year till date, February 20, 2025, and by 2.45% alone in the month of February. It seems the bears are dominating the bulls. YouTube's so-called finfluencers are proclaiming this is a crash and claiming that the market will decline even more, making such comments as "the market will crash even more." Is this actually a crash or a correction, though? As for YouTubers, they only care about getting views on their videos. They know that if they put "CRASH" in bold letters on their thumbnails, their videos will attract more views. So, in today’s blog, we’ll discuss the truth behind the hype—what’s really happening in the market. Before we determine whether this is a crash or a correction, we must know what these terms mea...